Biora Therapeutics, Inc. (PROG)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Biora Therapeutics, Inc. (PROG)
Company Performance

Current Price

as of Oct 16, 2024

$0.59

P/E Ratio

N/A

Market Cap

$21.52M

Description

Biora Therapeutics, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. Its products include the Preparent Carrier Test, Innatal Prenatal Screen, Riscover Hereditary Cancer Test, and Resura Prenatal Test. The company was founded by Paul W. Hawran and Harry Stylli in 2010 and is headquartered in San Diego, CA.

Metrics

Overview

  • HQSan Diego, CA
  • SectorHealth Services
  • IndustryMedical/Nursing Services
  • TickerPROG
  • Price$0.59+6.61%

Trading Information

  • Market Cap$21.52M
  • Float92.77%
  • Average Daily Volume (1m)287,835
  • Average Daily Volume (3m)210,790
  • EPS-$5.47

Company

  • Revenue$0.86M
  • Rev Growth (1yr)15,800.00%
  • Net Income$6.47M
  • Gross Margin65.41%
  • EBITDA Margin-4,929.56%
  • EBITDA-$15.68M
  • EV$90.62M
  • EV/Revenue105.37
  • P/EN/A
  • P/S50.92
  • P/BN/A
Documents
Factset Street Account
StreetAccount Earnings Call Q&A Summary: Biora Therapeutics Q3 (2023-11-22T19:21:21Z)
Biora Therapeutics to submit updated IND application for BT-600 ($2.44, 0.00) (2023-10-23T21:32:54Z)
Biora Therapeutics submits updated IND Application for BT-600 ($2.02, 0.00) (2023-10-30T20:16:08Z)
Biora Therapeutics reports Q3 EPS ($4.89) vs year-ago ($0.68) ($1.34, 0.00) (2023-11-13T21:13:01Z)
Biora Therapeutics presents data on the BioJet systemic oral delivery platform in short oral discussion at 59th European Association for the Study of Diabetes ($2.18, 0.00) (2023-10-05T12:07:20Z)
Biora Therapeutics announces new patent for its NaviCap targeted oral delivery platform ($1.19, 0.00) (2023-12-19T13:06:36Z)
Biora Therapeutics announces FDA clearance of IND application for drug/device combination BT-600 targeting treatment of ulcerative colitis ($1.24, 0.00) (2023-11-30T21:49:42Z)
Biora Therapeutics announces convertible note exchange agreement ($1.36, 0.00) (2023-12-18T13:11:49Z)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report 2021Q4
Earnings Report (2022-03-28)
Factset
Factset Business Description